VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Patrick M. Forde on Next Steps After CheckMate-026 Study in NSCLC

Patrick M. Forde, MBBCh
Published: Thursday, Nov 10, 2016


Patrick M. Forde, MBBCh, assistant professor of oncology, Johns Hopkins Hospital, discusses the CheckMate-026 study, which demonstrated that first-line therapy with nivolumab failed to improve progression-free survival (PFS) in PD-L1–positive non-small cell lung cancer (NSCLC) compared with standard chemotherapy.

Nivolumab-treated patients had a median PFS of 4.2 months compared with 5.9 months for patients treated with a chemotherapy doublet chosen by the treating physician. Overall survival (OS) and response rate also did not differ significantly between treatment groups.
 
In the second-line treatment of lung cancer in patients that have already received platinum-based doublet chemotherapy, nivolumab does appear to prolong survival over chemotherapy. A lot of oncologists expected to see a similar finding in the first-line setting, says Forde.
 
It will be very important to look at the population of patients enrolled in the CheckMate-026 study and determine what characteristics of the tumor and the immune environment may have predicted or not predicted response to treatment. There is a lot of work to be done looking back at specimens from that trial to try and determine exactly why nivolumab did not improve survival in this study, says Forde.

Patrick M. Forde, MBBCh, assistant professor of oncology, Johns Hopkins Hospital, discusses the CheckMate-026 study, which demonstrated that first-line therapy with nivolumab failed to improve progression-free survival (PFS) in PD-L1–positive non-small cell lung cancer (NSCLC) compared with standard chemotherapy.

Nivolumab-treated patients had a median PFS of 4.2 months compared with 5.9 months for patients treated with a chemotherapy doublet chosen by the treating physician. Overall survival (OS) and response rate also did not differ significantly between treatment groups.
 
In the second-line treatment of lung cancer in patients that have already received platinum-based doublet chemotherapy, nivolumab does appear to prolong survival over chemotherapy. A lot of oncologists expected to see a similar finding in the first-line setting, says Forde.
 
It will be very important to look at the population of patients enrolled in the CheckMate-026 study and determine what characteristics of the tumor and the immune environment may have predicted or not predicted response to treatment. There is a lot of work to be done looking back at specimens from that trial to try and determine exactly why nivolumab did not improve survival in this study, says Forde.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x